Evaluation of Asthma and Allergic Rhinitis Risks in Patients with Atopic Dermatitis Undergoing Treatment with Biologics and JAK Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials - Scorecard - MDSpire
Advertisement
Evaluation of Asthma and Allergic Rhinitis Risks in Patients with Atopic Dermatitis Undergoing Treatment with Biologics and JAK Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Clinical Scorecard: Evaluation of Asthma and Allergic Rhinitis Risks in Patients with Atopic Dermatitis Undergoing Treatment with Biologics and JAK Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
At a Glance
Category
Detail
Condition
Atopic Dermatitis (AD)
Key Mechanisms
Th2-driven cytokines and JAK-STAT signaling pathways
Target Population
Patients with Atopic Dermatitis, regardless of age or geographic region
Care Setting
Clinical trials
Key Highlights
AD has a global prevalence of 15%-20% in children and 6%-10% in adults.
Recent therapies target key molecular pathways associated with AD.
Dupilumab treatment reduces the incidence of allergic events compared to placebo.
Network meta-analysis provides evidence for personalized treatment decisions.
Study included 26 randomized controlled trials.
Guideline-Based Recommendations
Diagnosis
Diagnosis of AD per American Academy of Dermatology guidelines.
Management
Utilize systemic JAK inhibitors or biologics for treatment.
Monitoring & Follow-up
Monitor for asthma and allergic rhinitis adverse events during follow-up.
Risks
Assess the risk of new-onset asthma and allergic rhinitis with systemic therapies.
Patient & Prescribing Data
Patients with diagnosed Atopic Dermatitis.
FDA-approved therapies include four biologics and two JAK inhibitors.
Clinical Best Practices
Conduct comprehensive literature searches for RCTs on AD treatments.
Employ Bayesian NMA for analyzing treatment effects.
Utilize the Cochrane RoB 2 tool for quality assessment of studies.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
